Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

OCTOBER 6, 2021

MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. About Flora Growth Corp.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 9, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Investors may register for the conference at the event website. During this presentation, Chris Chapman, M.D.,

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co.,

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JULY 29, 2021

All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

DECEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. in the blood. MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging lifespan. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. Business highlights. LONDON, Aug.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

AUGUST 25, 2021

TORONTO–(BUSINESS WIRE)– $HUGE #RestoreFSD –FSD Pharma Inc. The Consideration Shares may be adjusted slightly in the event the market price of the FSD Shares changes significantly prior to closing of the Transaction. million) in FSD Pharma stock (the “ Transaction ”), as further described below.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

JUNE 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

JUNE 4, 2021

Clinical trial information: NCT03276572 ( [link] ). The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. Abstract Number: 5015. Date and Time: Available Starting June 4, 2021 , 9:00 am (EST).

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 12, 2021

Business Cann Report. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP). OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

JULY 28, 2021

We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinical trial under an FDA IND approval.” ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

JUNE 15, 2021

VANCOUVER, British Columbia–(BUSINESS WIRE)– Brains Bioceutical Corp. Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. Brains” or the “Company”) is pleased to announce the completion of a USD $31.9

Pharmaceutical 63

Pharmaceutical Clinical Trials Research and Development Events 63

Cannabis Law Report

JULY 9, 2021

The Index is designed to provide exposure to the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. –(BUSINESS WIRE)– $APDN #COVID19 — Applied DNA Sciences, Inc. Hayward, president and CEO of Applied DNA.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

JANUARY 27, 2022

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Fragile X Syndrome” report has been added to ResearchAndMarkets.com’s offering. The US has a substantial lead in the number of FXS clinical trials globally. Clinical trial activity in the FXS space is dominated by completed trials.

Clinical Trials 40

Clinical Trials Therapy Cannabinoids Topical 40

Cannabis Law Report

SEPTEMBER 2, 2021

–(BUSINESS WIRE)– $APDN #COVID19Testing — Applied DNA Sciences, Inc. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. STONY BROOK, N.Y.–(BUSINESS Food and Drug Administration (U.S.

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

SpeedWeed

AUGUST 16, 2021

and industry-leading Cannabis Business Times, Cannabis Dispensary, and Hemp Grower magazines, announces today President of Scottsdale Research Institute (SRI) Sue Sisley, MD, as the keynote speaker on Day 2 of its annual event, to take place Aug. 24-26, 2021, at Paris Las Vegas Hotel & Casino. 25 from 11 a.m. – 24-26, 2021.

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. BERWYN, Pa.–(BUSINESS Mack, Chairman and CEO of Virpax. Christopher M. Chipman, CPA. Chief Financial Officer. Betsy Brod.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials. The frequency of treatment-emergent adverse events (TEAE) was 62.9% ET (12:00 p.m. RADNOR, Pa.–(BUSINESS

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

SEPTEMBER 22, 2021

PETACH TIKVA, Israel–(BUSINESS WIRE)– Can-Fite BioPharma Ltd. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Investors are invited to view the presentation and the panel here: link.

Clinical Trials 40

Clinical Trials Treatment Business Events 40

Cannabis Law Report

JANUARY 6, 2022

Tim Leslie brings significant experience in both the cannabis industry and international growth and business development, including an extensive career at Amazon, to the organization. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. Visit www.floragrowth.com or follow @floragrowthcorp on social for more information.

Research and Development 52

Research and Development Events Clinical Trials Business 52

Cannabis Law Report

OCTOBER 5, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Investors can register for the event here and view the live presentation here. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction.

Pharmaceutical 40

Pharmaceutical Clinical Trials Cannabinoids Events 40

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Since March 2019, Mr. Allen has served as Chief Business Officer of Ambrx Biopharma Inc. Simon is a tremendous leader with significant commercial and business development experience, which are the most relevant skills for Anebulo at this stage.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

FEBRUARY 2, 2022

– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. Visit www.floragrowth.com or follow @floragrowthcorp on social for more information.

Cannabinoids 40

Cannabinoids Clinical Trials Events Cultivation 40

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study at a single site in the Netherlands to evaluate ANEB-001 in the inhibition of THC-induced effects. Affirms expectations for initial topline results in 1H 2022.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52